immuno-oncology Archives -

Market Access/ News/ News/ News/ News/ Oncology/ Patients

Opdivo backed by NICE for rare gastro-oesophageal cancers

Phil Taylor Bristol-Myers Squibb, gastric cancer, HEOR, immuno-oncology, Keytruda, Merck & Co, oesophageal cancer, Oncology, Opdivo 0 Comment

Bristol-Myers Squibb’s Opdivo has been recommended as a treatment for around 3,000 people with rare forms of gastro-oesophageal

Opdivo backed by NICE for rare gastro-oesophageal cancers

https://pharmaphorum.com/news/opdivo-backed-by-nice-for-rare-gastro-oesophageal-cancers/

News/ News/ News/ Oncology/ R&D

GSK’s pullback from cell therapy continues as Immatics alliance ends

Phil Taylor cell therapy, GlaxoSmithKline, Immatics, immuno-oncology, Oncology, partnering, TCR 0 Comment

Immatics has become the latest partner for GSK in the area of cell therapy for cancer to see

GSK’s pullback from cell therapy continues as Immatics alliance ends

https://pharmaphorum.com/news/gsks-pullback-from-cell-therapy-continues-as-immatics-alliance-ends/

Cancer/ News/ News/ News/ Oncology/ R&D

Normunity de-stealths, launches Series A immune normalisers

Nicole Raleigh Canaan Ventures, cancer, immuno-oncology, immunotherapy, Lieping Chen, Normunity, Oncology, PD1-L1, Rachel Humphrey, Series A financing 0 Comment

Biotech start-up Normunity, Inc. has exited stealth with a $65 million Series A to create a new class

Normunity de-stealths, launches Series A immune normalisers

https://pharmaphorum.com/news/normunity-de-stealths-launches-series-a-immune-normalisers/

Market Access/ News/ News/ News/ Oncology

J&J nabs FDA okay for BCMA bispecific Tecvayli

Phil Taylor BCMA, bispecific antibody, Haematology, immuno-oncology, Johnson & Johnson, multiple myeloma, Oncology, regulatory approval, Tecvayli 0 Comment

Johnson & Johnson has secured another regulatory approval for its BCMAxCD3 bispecific antibody for multiple myeloma – Tecvayli

J&J nabs FDA okay for BCMA bispecific Tecvayli

https://pharmaphorum.com/news/jj-nabs-fda-okay-for-bcma-bispecific-tecvayli/

AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

Market Access/ News/ News/ News/ Oncology

AstraZeneca gets first okay for CTLA4 drug tremelimumab

Phil Taylor AstraZeneca, Bristol-Myers Squibb, Imfinzi, Imjudo, immuno-oncology, Liver cancer, Oncology, regulatory approval, tremelimumab, Yervoy 0 Comment

AstraZeneca’s lengthy and turbulent development of CTLA4 inhibitor tremelimumab has at least led to a regulatory approval as

AstraZeneca gets first okay for CTLA4 drug tremelimumab

https://pharmaphorum.com/news/astrazeneca-gets-first-fda-okay-for-ctla4-drug-tremelimumab/

Market Access/ News/ News/ News/ Oncology

Atara closes on first approval of transplant complication therapy

Phil Taylor allogeneic, Atara Biotherapeutics, cell therapy, Ebvallo, immuno-oncology, Oncology, Pierre Fabre, tabelecleucel 0 Comment

Atara Biotherapeutics’ cell therapy Ebvallo should be approved to treat Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD), according

Atara closes on first approval of transplant complication therapy

https://pharmaphorum.com/news/atara-closes-on-first-approval-of-transplant-complication-therapy/

Cancer/ Oncology/ Views & Analysis/ Views and analysis

Bringing the promise of immunotherapy to a broader population

mike.hammerton@pharmaphorum.com cancer care, Faron, immuno-oncology, immunotherapy, Oncology, tumour microenvironment 0 Comment

When James P Allison and Tasuku Honjo were awarded the Nobel Prize for Medicine in 2018 for their

Bringing the promise of immunotherapy to a broader population

https://pharmaphorum.com/views-and-analysis/bringing-the-promise-of-immunotherapy-to-a-broader-population/

News/ News/ News/ Oncology/ R&D

Merck gets on board with Moderna cancer vaccine in $250m deal

Phil Taylor cancer vaccine, immuno-oncology, melanoma, Merck & Co, Moderna, Oncology, partnering, personalised medicine 0 Comment

Shares in Moderna were ticking upwards today after Merck & Co took up an option on a personalised

Merck gets on board with Moderna cancer vaccine in $250m deal

https://pharmaphorum.com/news/merck-gets-on-board-with-moderna-cancer-vaccine-in-250m-deal/

News/ News/ News/ Oncology/ Sales and Marketing

Immutep’s LAG-3 drug ‘dramatically undervalued,’ says analyst

Phil Taylor Bristol-Myers Squibb, eftilagimod alpha, immuno-oncology, Immutep, Non-small cell lung cancer, Oncology, Opdualag 0 Comment

Australian biotech Immutep’s LAG-3 checkpoint inhibitor eftilagimod alpha (efti) may not be the first drug in the class

Immutep’s LAG-3 drug ‘dramatically undervalued,’ says analyst

https://pharmaphorum.com/news/immuteps-lag-3-drug-dramatically-undervalued-says-analyst/

Trending

immuno-oncology

Login